GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabion SA (WAR:MAB) » Definitions » Short Interest

Mabion (WAR:MAB) Short Interest


View and export this data going back to 2010. Start your Free Trial

What is Mabion Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Mabion's Short Interest

For the Biotechnology subindustry, Mabion's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mabion's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabion's Short Interest distribution charts can be found below:

* The bar in red indicates where Mabion's Short Interest falls into.


;
;

Mabion Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabion SA (WAR:MAB) » Definitions » Short Interest
Comparable Companies
WAR:PTG WAR:CTX WAR:MOC WAR:URT WAR:NNG WAR:RDG WAR:PHR WAR:PUR WAR:GX1 WAR:RNT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Website
https://www.mabion.eu
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.

Mabion Headlines